MarketCap
Facebook
X
Telegram
The Procter & Gamble Company Income Statement 2025-2011 | PG
Brief overview of financial performance at The Procter & Gamble Company
The overview follows changes across a five-year period. According to figures from The Procter & Gamble Company, revenue changed from 71 billion dollars to 84.3 billion dollars over five years. The total change was +18.8%, with a CAGR of approximately 3.5%. The revenue trend is close to stagnation.
The five-year change in gross profit reached +20.8%: from 35.7 billion dollars to 43.1 billion dollars. Cost of revenue moved broadly in line with sales. Gross profit as a share of revenue changed from 50.3% to 51.2%. The gross margin stayed within a similar range.
The operating result measured by EBITDA moved from $18.7 billion to $23.3 billion, or +24.5%. EBITDA broadly followed the top-line trend. EBITDA margin was 26.4% at the start and 27.6% at the end. Operating profitability remained broadly stable.
Over the period, net income shifted from 13 billion dollars to 16 billion dollars (+22.6%). The final year delivered the highest net income in the period.
Market value was 333 billion dollars at the start and 354 billion dollars at the end. Market value followed a broadly neutral trajectory.
Conclusion
The five-year picture requires weighing both strengths and weaknesses. The positive side is supported by an improving EBITDA margin, steady gross profitability and a stronger final result. Caution is warranted because of a softer top-line trend. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement The Procter & Gamble Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
354 B | 397 B | 368 B | 334 B | 399 B | 333 B | 324 B | 203 B | 238 B | 237 B | 218 B | 217 B | 225 B | 183 B | 172 B |
Shares |
2.35 B | 2.36 B | 2.37 B | 2.41 B | 2.47 B | 2.49 B | 2.69 B | 2.53 B | 2.64 B | 2.77 B | 2.81 B | 2.78 B | 2.8 B | 2.82 B | 2.8 B |
Historical Prices |
151 | 168 | 155 | 139 | 162 | 134 | 118 | 83.9 | 81.1 | 72 | 65.7 | 73.1 | 63.3 | 51.2 | 48.7 |
Net Income |
16 B | 14.9 B | 14.7 B | 14.7 B | 14.3 B | 13 B | 3.9 B | 9.75 B | 15.3 B | 10.5 B | 7.04 B | 11.6 B | 11.3 B | 10.8 B | 11.8 B |
Revenue |
84.3 B | 84 B | 82 B | 80.2 B | 76.1 B | 71 B | 67.7 B | 66.8 B | 65.1 B | 65.3 B | 76.3 B | 83.1 B | 84.2 B | 83.7 B | 82.6 B |
Cost of Revenue |
41.2 B | 40.8 B | 42.8 B | 42.2 B | 37.1 B | 35.2 B | 34.8 B | 34.4 B | 32.6 B | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 32.9 B | 32.6 B | 32.5 B | 32.4 B | 37.4 B | 40.6 B | 41.7 B | 41.3 B | 41.8 B |
Operating Income |
20.5 B | 18.5 B | 18.1 B | 17.8 B | 18 B | 15.7 B | 5.49 B | 13.4 B | 13.8 B | 13.3 B | 11 B | 13.9 B | 13.1 B | 13 B | 15.5 B |
Interest Expense |
154 M | 668 M | 668 M | 570 M | 502 M | 465 M | 509 M | 506 M | 465 M | 579 M | 626 M | 709 M | 668 M | 769 M | 831 M |
EBITDA |
23.3 B | 21.4 B | 20.8 B | 20.6 B | 20.7 B | 18.7 B | 16.7 B | 16.5 B | 16.8 B | 16.5 B | 17 B | 18.4 B | 17.8 B | 18.1 B | 18.7 B |
Operating Expenses |
- | - | - | - | - | - | 19.1 B | 18.9 B | 18.6 B | 18.9 B | 23.6 B | 25.3 B | 27 B | 26.4 B | 26 B |
General and Administrative Expenses |
22.7 B | 23.3 B | 21.1 B | 20.2 B | 21 B | 20 B | 19.1 B | 18.9 B | 18.6 B | 18.9 B | 23.6 B | 25.3 B | 27 B | 26.4 B | 26 B |
All numbers in USD currency
Quarterly Income Statement The Procter & Gamble Company
| 2026-Q1 | 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
2.33 B | 2.34 B | 2.35 B | 2.35 B | 2.36 B | 2.36 B | 2.36 B | 2.36 B | 2.36 B | 2.37 B | 2.39 B | 2.38 B | 2.4 B | 2.41 B | 2.43 B | 2.42 B | 2.46 B | 2.48 B | 2.49 B | 2.48 B | 2.49 B | 2.49 B | 2.5 B | 2.49 B | 2.5 B | 2.5 B | 2.5 B | 2.5 B | 2.5 B | 2.53 B | 2.55 B | 2.53 B | 2.55 B | 2.6 B | 2.67 B | 2.6 B | 2.67 B | 2.72 B | 2.72 B | 2.72 B | 2.72 B | 2.71 B | 2.71 B | - | 2.71 B | - | 2.74 B | - | - | - | - | - | - | - | - | - | - |
Net Income |
3.93 B | 4.75 B | 3.77 B | 4.63 B | 3.96 B | 3.75 B | 3.47 B | 4.52 B | 3.4 B | 3.93 B | 3.94 B | 7.87 B | 3.36 B | 4.22 B | 4.11 B | 8.34 B | 3.27 B | 3.85 B | 4.28 B | 3.85 B | 2.92 B | 3.72 B | 3.59 B | -5.24 B | 2.74 B | 3.19 B | 3.2 B | 1.89 B | 3.2 B | 2.5 B | 2.85 B | 2.5 B | 2.85 B | 7.88 B | 2.71 B | 7.88 B | 2.71 B | 3.21 B | 2.6 B | 3.21 B | 2.6 B | 2.37 B | 1.99 B | 2.37 B | 1.99 B | 3.43 B | 3.03 B | 3.43 B | 3.03 B | 4.06 B | 2.81 B | 4.06 B | 2.81 B | 1.69 B | 3.02 B | 1.69 B | 3.02 B |
Revenue |
21.2 B | 22.4 B | 19.8 B | 21.9 B | 21.7 B | 20.2 B | 21.4 B | 21.9 B | 20.1 B | 20.8 B | 20.6 B | 41.4 B | 19.4 B | 21 B | 20.3 B | 41.3 B | 18.1 B | 19.7 B | 19.3 B | 19.7 B | 19.3 B | 18.2 B | 17.8 B | 18.2 B | 17.8 B | 17.4 B | 16.7 B | 16.5 B | 16.3 B | 17.4 B | 16.7 B | 17.4 B | 16.7 B | 16.9 B | 16.5 B | 16.9 B | 16.5 B | 16.9 B | 16.5 B | 16.9 B | 16.5 B | 18.5 B | 18.8 B | 20.2 B | 20.8 B | 19.3 B | 18.8 B | 22.3 B | 21.2 B | 21.7 B | 20.3 B | 22.2 B | 20.7 B | 21.7 B | 21.5 B | 22.1 B | 21.9 B |
Cost of Revenue |
10.7 B | 10.9 B | 9.69 B | 10.4 B | 10.4 B | 9.86 B | 10.1 B | 10.5 B | 10.4 B | 10.9 B | 10.8 B | 21.7 B | 10.3 B | 10.7 B | 10.4 B | 21 B | 8.92 B | 9.25 B | 9.14 B | 9.25 B | 9.14 B | 8.87 B | 8.72 B | 8.87 B | 8.72 B | 8.92 B | 8.48 B | 8.92 B | 8.48 B | 8.71 B | 8.27 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
4.58 B | 5.86 B | 4.56 B | 5.74 B | 5.8 B | 4.46 B | 4.43 B | 5.77 B | 4.25 B | 4.78 B | 4.94 B | 9.72 B | 4.02 B | 5.17 B | 5.02 B | 10.2 B | 3.78 B | 5.38 B | 5.28 B | 5.38 B | 5.28 B | 4.48 B | 4.29 B | 4.48 B | 4.29 B | 3.9 B | 3.55 B | 3.9 B | 3.55 B | 3.92 B | 3.65 B | 4 B | 3.74 B | 3.83 B | 3.73 B | 3.88 B | 3.77 B | 3.85 B | 3.77 B | 3.85 B | 3.77 B | 3.58 B | 3.63 B | 3.95 B | 2.94 B | 3.89 B | 3.83 B | 4.55 B | 4.15 B | 4.43 B | 3.89 B | 4.49 B | 3.95 B | 2.68 B | 4.25 B | 2.74 B | 4.33 B |
Interest Expense |
537 M | 268 M | 210 M | 224 M | -554 M | 260 M | 177 M | 132 M | 222 M | 171 M | 123 M | 294 M | 109 M | 106 M | 109 M | 215 M | 106 M | 143 M | 136 M | 143 M | 136 M | 100 M | 108 M | 100 M | 108 M | 138 M | 129 M | 138 M | 129 M | 122 M | 115 M | 122 M | 115 M | 122 M | 131 M | 122 M | 131 M | 143 M | 140 M | 143 M | 140 M | 160 M | 170 M | 160 M | 169 M | 185 M | 165 M | 187 M | 165 M | 169 M | 172 M | 169 M | 172 M | 201 M | 207 M | 201 M | 207 M |
EBITDA |
5.36 B | 6.62 B | 5.25 B | 5.82 B | 6.52 B | 4.54 B | 4.52 B | 6.47 B | 4.33 B | 4.86 B | 5.6 B | 11 B | 4.1 B | 5.24 B | 5.73 B | 11.6 B | 3.86 B | 5.46 B | 5.95 B | 6.72 B | 5.95 B | 4.57 B | 5.01 B | 5.88 B | 5.01 B | 3.98 B | 4.2 B | 5.19 B | 4.2 B | 3.99 B | 4.34 B | 5.37 B | 4.43 B | 3.91 B | 4.46 B | 5.31 B | 4.5 B | 3.95 B | 4.5 B | 5.31 B | 4.5 B | 3.7 B | 4.43 B | 5.49 B | 3.73 B | 4.02 B | 4.6 B | 6.08 B | 4.92 B | 4.55 B | 4.6 B | 5.94 B | 4.66 B | 2.8 B | 4.99 B | 4.2 B | 5.08 B |
General and Administrative Expenses |
5.94 B | 5.64 B | 5.52 B | 5.72 B | 5.52 B | 5.88 B | 5.52 B | 5.6 B | 5.42 B | 5.09 B | 4.83 B | 9.92 B | 5.03 B | 5.12 B | 4.95 B | 10.1 B | 5.4 B | 5.11 B | 4.9 B | 5.11 B | 4.9 B | 4.89 B | 4.78 B | 4.89 B | 4.78 B | 4.62 B | 4.65 B | 4.62 B | 4.65 B | 4.77 B | 4.74 B | 4.72 B | 4.69 B | 4.68 B | 4.64 B | 4.68 B | 4.64 B | 4.6 B | 4.61 B | 4.6 B | 4.61 B | 5.36 B | 5.4 B | 6.13 B | 6.33 B | 6.32 B | 6.14 B | 6.6 B | 6.24 B | 6.8 B | 6.44 B | 6.8 B | 6.44 B | 6.66 B | 6.47 B | 6.72 B | 6.52 B |
All numbers in USD currency
The income statement is one of the three key financial reports of a company The Procter & Gamble Company (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Household products industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Natura &Co Holding S.A.
NTCO
|
- | - | $ 9.02 B | - |
 |
Spectrum Brands Holdings
SPB
|
$ 88.81 | 1.58 % | $ 2.28 B |  USA |
 |
United-Guardian
UG
|
$ 7.62 | -1.8 % | $ 35 M | USA |
 |
Unilever PLC
UL
|
$ 60.94 | 1.21 % | $ 133 B |  Britain |
 |
Acme United Corporation
ACU
|
$ 53.94 | 3.97 % | $ 204 M | USA |
 |
Dogness (International) Corporation
DOGZ
|
$ 0.95 | -0.05 % | $ 12.7 M |  China |
 |
Revlon
REV
|
- | -4.41 % | $ 212 M | USA |
 |
e.l.f. Beauty
ELF
|
$ 77.36 | 1.59 % | $ 4.24 B | USA |
 |
Coty
COTY
|
$ 2.65 | 1.73 % | $ 2.31 B | USA |
 |
Hims & Hers Health
HIMS
|
$ 28.09 | -14.2 % | $ 6.32 B | USA |
 |
Helen of Troy Limited
HELE
|
$ 28.47 | 6.07 % | $ 655 M |  Bermuda |
 |
Edgewell Personal Care Company
EPC
|
$ 27.63 | 3.52 % | $ 1.31 B | USA |
 |
The Clorox Company
CLX
|
$ 95.55 | 1.87 % | $ 11.8 B | USA |
 |
Church & Dwight Co.
CHD
|
$ 97.64 | 1.52 % | $ 23.7 B | USA |
 |
Newell Brands
NWL
|
$ 5.08 | 0.99 % | $ 2.12 B | USA |
 |
Kimberly-Clark Corporation
KMB
|
$ 109.7 | 2.23 % | $ 36.4 B | USA |
 |
Nature's Sunshine Products
NATR
|
$ 20.4 | -0.58 % | $ 367 M | USA |
 |
Nu Skin Enterprises
NUS
|
$ 5.08 | - | $ 250 M | USA |
 |
LifeVantage Corporation
LFVN
|
$ 6.53 | 4.15 % | $ 80 M | USA |
 |
The Estée Lauder Companies
EL
|
$ 80.29 | 0.46 % | $ 28.9 B | USA |
 |
USANA Health Sciences
USNA
|
$ 21.32 | 1.91 % | $ 395 M | USA |
 |
Mannatech, Incorporated
MTEX
|
$ 4.5 | -3.43 % | $ 8.55 M | USA |
 |
Colgate-Palmolive Company
CL
|
$ 90.75 | 0.74 % | $ 73.4 B | USA |
 |
Inter Parfums
IPAR
|
$ 122.55 | 2.34 % | $ 3.93 B | USA |